Misbranding of Ziagen as Combivir.
Tampering leads to mislabeled HIV medsAbacavir (Ziagen) and lamivudine/zidovudine (Combivir), both from GlaxoSmithKline, are the subject of a Dear Pharmacy Professional letter issued by the FDA and the company following the discovery of misbranding of Ziagen as Combivir. According to the manufacturer, the incident appears to be caused by third-party tampering and is limited to one pharmacy in California. So far, only two 60-count bottles labeled as Combivir tablets contained Ziagen. The counterfeit labels were identified as Lot No. 6ZP9760 with expiration dates of April 2010 and April 2009. Pharmacists are encouraged to examine the contents of each bottle of Combivir to confirm that it contains the correct drug. If a bottle is discovered containing anything but Combivir, pharmacists should notify the GSK Response Center at 1-(888) 825-5249.